MacroGenics Inc
Change company Symbol lookup
Select an option...
MGNX MacroGenics Inc
CBZ CBIZ Inc
PSEC Prospect Capital Corp
SPEC Spectralcast Inc
RC Ready Capital Corp
GNK Genco Shipping & Trading Ltd
NVOS Novo Integrated Sciences Inc
PDRDF Pernod Ricard SA
RKDA Arcadia Biosciences Inc
BBVA Banco Bilbao Vizcaya Argentaria SA
Go

Health Care : Biotechnology | Small Cap Value
Company profile

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Closing Price
$3.98
Day's Change
0.08 (2.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.15
Day's Low
3.79
Volume
(Below Average)
Volume:
815,561

10-day average volume:
1,005,652
815,561

Wells Fargo wins termination of 2015 regulatory order

12:23 pm ET January 20, 2022 (MarketWatch)
Print

Wells Fargo & Co. (WFC) on Thursday confirmed that the Office of the Comptroller of the Currency (OCC) terminated a consent order from 2015 stemming from billing and marketing practices on identity and debt cancellation products offered by the bank. "The OCC believes that the safety and soundness of the bank and its compliance with laws and regulations does not require the continued existence of the order," the federal regulatory agency said in a legal document posted on its website. The OCC had charged the bank in 2015 with deficiencies in the bank's practices and issued a cease and desist order. Wells Fargo said the termination of the 2015 OCC order fits its "top priority" to build a risk and control infrastructure that's "appropriate for its size and complexity." Shares of Wells Fargo rose 0.6% on Thursday after gaining 16.5% so far in 2022. The stock is up 72.1% in the past year, ahead of the 19% gain by the S&P 500 .

-Steve Gelsi

	

(END) Dow Jones Newswires

January 20, 2022 12:23 ET (17:23 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.